Comparing therapeutic benefit and risk

Therapie

Volumn 54, Issue 1, 1999, Pages 29-34

  Meyboom, R H B ^a   Egberts, A C G ^b,c  

^a Netherlands Pharmacovigilance Centre   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c CPRLab   (Netherlands)

Author keywords

Decision analysis; Evaluation; Risk benefit ratio

Indexed keywords

CONFERENCE PAPER; DRUG SAFETY; HOSPITAL ADMISSION; INFORMATION PROCESSING; MEDICAL DECISION MAKING; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RISK BENEFIT ANALYSIS;

DRUG THERAPY; HUMANS; MODELS, STATISTICAL; PHARMACEUTICAL PREPARATIONS; RISK ASSESSMENT; TREATMENT FAILURE;

EID: 0032970493     PISSN: 00405957     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (15)

1. Nelson KF, Talbert PL. Drug-related hospital admissions. Pharmacotherapy 1996; 16: 701-707.
2. Imbs JL, Pouyanne P, Haramburu F et al. Iatrogenie médicamenteuse: estimation de sa prévalence dans les hôpitaux publics français. Thérapie 1999; 34: 21-27.
3. Lazarou JP, Pomeranz BH, Corey PH. Incidence of adverse drug reactions in hospitalized patients. JAMA 1998; 279: 1200-1205.
4. Classen DC, Pestotnik GL, Evans RS, Lloyd JF, Burke JP. Adverse drug events in hospitalized patients. Excess length of stay, extra costs and attributed mortality. JAMA 1997; 277: 301-306.
5. Spilker B. Guide to Clinical Trials. New York: Raven Press, 1991.
6. Inman WHW, Ed. Monitoring for Drug Safety. Lancaster: MTP Press, 1986.
7. Strom BL, ed. Pharmacoepidemiology, 2nd Edition. Chichester: John Wiley, 1994.
8. Stephens MDB. The detection of new adverse drug reactions. 2nd Edition. London: Macmillan Press, 1992.
9. Meyboom RHB, Egberts ACG, Hekster YA et al. Principles of signal detection in pharmacovigilance. Drug Safety 1997; 16: 355-365.
10. Ory RW. Mortality associated with fertility and fertility control. Fam Plann Perspect 1983; 15: 57.
11. Lebech PE, Ottesen B. Sex hormones and related compounds, including oral contraceptives. In: Dukes MNG, Elis J. Side Effects of Drugs Annual 8. Amsterdam: Elsevier, 1984: 355-370.
12. CIOMS Working Group. Benefit-risk balance for marketed drugs: evaluating safety signals. Report of CIOMS Working Group IV, 1988. [CIOMS, c/o World Health Organization, Avenue Appia, 1211 Geneva 27, Switzerland.]
13. Meyboom RHB. Good practice in the post-marketing surveillance of medicines. Pharmacy World Science 1997; 19: 186-190.
14. Edwards IR, Wiholm BE, Martinez C. Concepts in risk-benefit assessment. A simple merit analysis of a medicine? Drug Safety 1996; 15: 1-7.
15. MacDonald TM, Morant SV, Robinson GO et al. Association of upper gastrointestinal toxicity of non-steroidal anti-inflammatory drugs with continued exposure: cohort study. BMJ 1997; 315: 1333-1337.